ES2393815T3 - Agonistas opioides kappa para el tratamiento de síndrome del intestino irritable con diarrea predominante y alternante - Google Patents

Agonistas opioides kappa para el tratamiento de síndrome del intestino irritable con diarrea predominante y alternante Download PDF

Info

Publication number
ES2393815T3
ES2393815T3 ES08731748T ES08731748T ES2393815T3 ES 2393815 T3 ES2393815 T3 ES 2393815T3 ES 08731748 T ES08731748 T ES 08731748T ES 08731748 T ES08731748 T ES 08731748T ES 2393815 T3 ES2393815 T3 ES 2393815T3
Authority
ES
Spain
Prior art keywords
ibs
ethyl
hydroxypyrrolidin
phenyl
diphenylacetamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08731748T
Other languages
English (en)
Spanish (es)
Inventor
Allen Mangel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tioga Pharmaceuticals Inc
Original Assignee
Tioga Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tioga Pharmaceuticals Inc filed Critical Tioga Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2393815T3 publication Critical patent/ES2393815T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
ES08731748T 2007-03-30 2008-03-07 Agonistas opioides kappa para el tratamiento de síndrome del intestino irritable con diarrea predominante y alternante Active ES2393815T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92084107P 2007-03-30 2007-03-30
US920841P 2007-03-30
PCT/US2008/056317 WO2008121496A1 (en) 2007-03-30 2008-03-07 Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome

Publications (1)

Publication Number Publication Date
ES2393815T3 true ES2393815T3 (es) 2012-12-28

Family

ID=39795494

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08731748T Active ES2393815T3 (es) 2007-03-30 2008-03-07 Agonistas opioides kappa para el tratamiento de síndrome del intestino irritable con diarrea predominante y alternante

Country Status (19)

Country Link
US (2) US7960429B2 (OSRAM)
EP (3) EP2636407A3 (OSRAM)
JP (2) JP5416085B2 (OSRAM)
KR (2) KR101208326B1 (OSRAM)
CN (2) CN102641265A (OSRAM)
AU (1) AU2008232954A1 (OSRAM)
BR (1) BRPI0809651A2 (OSRAM)
CA (1) CA2682608A1 (OSRAM)
CY (1) CY1113317T1 (OSRAM)
DK (1) DK2136801T3 (OSRAM)
ES (1) ES2393815T3 (OSRAM)
HR (1) HRP20120798T1 (OSRAM)
IL (1) IL201226A0 (OSRAM)
MX (1) MX2009010409A (OSRAM)
PL (1) PL2136801T3 (OSRAM)
PT (1) PT2136801E (OSRAM)
RU (1) RU2441655C2 (OSRAM)
SI (1) SI2136801T1 (OSRAM)
WO (1) WO2008121496A1 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2136801E (pt) * 2007-03-30 2012-12-06 Tioga Pharmaceuticals Inc Agonistas kappa-opiáceos para o tratamento do síndrome do intestino irritável com predomínio de diarreia ou alternância
WO2012012410A2 (en) * 2010-07-19 2012-01-26 Dr. Reddy's Laboratories Ltd. Kappa opioid receptor agonists
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
CA2893427C (en) 2012-12-24 2023-01-10 Neurogastrx, Inc. Methods for treating gi tract disorders
WO2015200369A1 (en) 2014-06-24 2015-12-30 Neurogastrx, Inc. Prodrugs of metopimazine
JP6410641B2 (ja) 2015-03-04 2018-10-24 ローム株式会社 ワイヤレス送電装置、異物検出方法、充電器
WO2018035046A1 (en) 2016-08-15 2018-02-22 President And Fellows Of Harvard College Treating infections using idsd from proteus mirabilis
ES2906979T3 (es) 2016-12-21 2022-04-21 Tioga Pharmaceuticals Inc Formulaciones farmacéuticas sólidas de asimadolina
WO2019122361A1 (en) 2017-12-22 2019-06-27 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Asimadoline for use in treating pulmonary diseases, vascular diseases, and sepsis
AU2019309913B2 (en) 2018-07-23 2025-02-27 Trevi Therapeutics, Inc. Treatment of chronic cough, breathlessness and dyspnea
AU2021206252A1 (en) 2020-01-10 2022-07-28 Trevi Therapeutics, Inc. Methods of administering nalbuphine
IL296368A (en) * 2020-03-18 2022-11-01 Cara Therapeutics Inc Oligosaccharide formulations of kappa opioid receptor agonists
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
EP3932390A1 (en) 2020-07-02 2022-01-05 Dr. August Wolff GmbH & Co. KG Arzneimittel Topical gel formulation containing asimadoline
JP7464744B2 (ja) * 2020-10-20 2024-04-09 セトラスホールディングス株式会社 診療支援装置、診療支援方法、診療支援プログラム及び診療支援システム
WO2022155332A1 (en) * 2021-01-13 2022-07-21 Blue Therapeutics, Inc. Methods of treating irritable bowel syndrome

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4192883A (en) 1976-04-09 1980-03-11 Pierre Fabre, S.A. Amides of pyrrolidinoethylamine which can be used in lung therapy
FR2421891A1 (fr) 1977-10-17 1979-11-02 Fabre Sa Pierre Obtention industrielle d'amides de la pyrrolidine ethyl amine
US4663343A (en) 1985-07-19 1987-05-05 Warner-Lambert Company Substituted naphthalenyloxy-1,2-diaminocyclohexyl amide compounds
US4889860A (en) 1985-09-23 1989-12-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4760069A (en) 1985-09-23 1988-07-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
GB8601796D0 (en) 1986-01-24 1986-02-26 Zambeletti Spa L Compounds
JPH02138254A (ja) 1988-02-23 1990-05-28 Glaxo Group Ltd 複素環誘導体
DE4034785A1 (de) 1990-11-02 1992-05-07 Merck Patent Gmbh 1-(2-arylethyl)-pyrrolidine
US5232978A (en) 1988-12-23 1993-08-03 Merck Patent Gesellschaft Mit Beschrankter Haftung 1-(2-arylethyl)-pyrrolidines
DE3935371A1 (de) 1988-12-23 1990-07-05 Merck Patent Gmbh Stickstoffhaltige ringverbindungen
US5389686A (en) 1989-02-20 1995-02-14 Jouveinal Sa Analgesic properties of fedotozine
DE3916663A1 (de) 1989-05-23 1990-11-29 Bayer Ag Substituierte (chinolin-2-yl-methoxy)phenyl-acyl-sulfonamide und -cyanamide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
US5232266A (en) 1989-07-24 1993-08-03 Mork William J Upholstered article of furniture with interchangeable seating module
CA2069423A1 (en) 1989-11-24 1991-05-25 Roberto Colle Azacyclic derivatives
GB8926560D0 (en) 1989-11-24 1990-01-17 Zambeletti Spa L Pharmaceuticals
US5300687A (en) 1991-07-18 1994-04-05 Ortho Pharmaceutical Corporation Trifluoromethylbenzylphosphonates useful in treating osteoporosis
DE4215213A1 (de) 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide
DE4425071C2 (de) 1994-07-15 1996-08-29 Degussa Verfahren zur Herstellung optisch aktiver Pyrrolidine mit hoher Enantiomerenreinheit
DE19523502A1 (de) 1995-06-28 1997-01-02 Merck Patent Gmbh Kappa-Opiatagonisten für entzündliche Darmerkrankungen
DE19531464A1 (de) 1995-08-26 1997-02-27 Merck Patent Gmbh N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid
EP1021204B1 (en) 1997-09-26 2005-12-28 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US20010051181A1 (en) 1997-12-22 2001-12-13 Van Osdol William W. Novel formulations for the transdermal administration of asimadoline
DE19827633A1 (de) 1998-04-20 1999-10-21 Merck Patent Gmbh Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid
AR019727A1 (es) 1998-06-30 2002-03-13 Takeda Chemical Industries Ltd Composicion farmaceutica
JP2000080047A (ja) 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
DE19849650A1 (de) * 1998-10-29 2000-05-04 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung des Irritable Bowel Syndroms (IBS)
EP1033364B1 (en) 1999-03-01 2005-02-23 Pfizer Products Inc. Cyano containing oxamic acids and derivatives as thyroid receptor ligands
US20020025948A1 (en) 2000-06-23 2002-02-28 Banks Bernard Joseph 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
GB0015562D0 (en) 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US6262062B1 (en) 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6569449B1 (en) 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
DE10116978A1 (de) 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
WO2003048113A1 (en) 2001-11-30 2003-06-12 Sepracor Inc. Tramadol analogs and uses thereof
JP2005531557A (ja) * 2002-05-17 2005-10-20 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 選択的オピエート受容体モジュレーターとして効果的な化合物の使用
MXPA05002983A (es) * 2002-09-18 2005-06-22 Univ Missouri Analogos de opiato selectivos del receptor opioide d.
DE10259245A1 (de) 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
JP2006522817A (ja) * 2003-04-08 2006-10-05 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 過敏性腸症候群を処置するための末梢オピオイドアンタゴニスト、特にメチルナルトレキソンの使用
ES2528669T3 (es) 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
PL1644021T3 (pl) * 2003-06-13 2013-01-31 Ironwood Pharmaceuticals Inc Sposoby i kompozycje do leczenia zaburzeń żołądkowo-jelitowych
WO2005046687A1 (en) * 2003-10-30 2005-05-26 Tioga Pharmaceuticals, Inc. Use of selective opiate receptor modulators in the treatment of neuropathy
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
PT2136801E (pt) * 2007-03-30 2012-12-06 Tioga Pharmaceuticals Inc Agonistas kappa-opiáceos para o tratamento do síndrome do intestino irritável com predomínio de diarreia ou alternância

Also Published As

Publication number Publication date
JP5416085B2 (ja) 2014-02-12
DK2136801T3 (da) 2012-12-17
CY1113317T1 (el) 2016-04-13
JP2010523492A (ja) 2010-07-15
CN102641265A (zh) 2012-08-22
EP2136801A1 (en) 2009-12-30
HRP20120798T1 (hr) 2012-11-30
EP2136801B1 (en) 2012-08-29
KR20100016004A (ko) 2010-02-12
JP2013173790A (ja) 2013-09-05
US20110046174A1 (en) 2011-02-24
MX2009010409A (es) 2010-03-29
AU2008232954A2 (en) 2011-12-01
EP2561870A1 (en) 2013-02-27
EP2636407A2 (en) 2013-09-11
KR101263225B1 (ko) 2013-05-13
SI2136801T1 (sl) 2013-01-31
CN101677997A (zh) 2010-03-24
PL2136801T3 (pl) 2013-01-31
WO2008121496A1 (en) 2008-10-09
RU2009140042A (ru) 2011-05-10
IL201226A0 (en) 2010-05-31
US7960429B2 (en) 2011-06-14
PT2136801E (pt) 2012-12-06
CA2682608A1 (en) 2008-10-09
BRPI0809651A2 (pt) 2014-10-07
AU2008232954A1 (en) 2008-10-09
KR20120058614A (ko) 2012-06-07
EP2636407A3 (en) 2013-11-06
CN101677997B (zh) 2012-05-09
RU2441655C2 (ru) 2012-02-10
KR101208326B1 (ko) 2012-12-05
US20080242720A1 (en) 2008-10-02
US8877800B2 (en) 2014-11-04
EP2136801A4 (en) 2010-05-26
HK1139860A1 (en) 2010-09-30

Similar Documents

Publication Publication Date Title
ES2393815T3 (es) Agonistas opioides kappa para el tratamiento de síndrome del intestino irritable con diarrea predominante y alternante
KR101615108B1 (ko) 중추 매개의 오심 및 구토를 치료하기 위한 조성물 및 방법
US20230087903A1 (en) Treatment of cns conditions
RU2008116931A (ru) Применение n-десметилклозапина для лечения нейропсихиатрических заболеваний у людей
RU2437661C2 (ru) Милнаципран в качестве средства для продолжительного лечения синдрома фибромиалгии
Evans et al. Persistent idiopathic facial pain.
AU2014244152A1 (en) Compositions to reduce pain comprising an opioid/toll-like receptor 4 antagonist, dextro enantiomers thereof, and methods of use therefor
JP2011517678A (ja) 過活動膀胱の治療のためのウデナフィル、およびアルフゾシンまたはオキシブチニンの組み合わせの使用
ES2198948T3 (es) Usos de antagonistas de la substancia p para el tratamiento del sindrome de la fatiga cronica y/o de la fibromialgia.
US11065273B2 (en) Treatment and prevention of alzheimer's disease (AD)
ES2668943T3 (es) Composición farmacéutica para tratar eyaculación precoz y método de tratamiento de la eyaculación precoz
HK1139860B (en) Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome
Liau et al. Efficacy and safety of barnidipine compared with felodipine in the treatment of hypertension in Chinese patients
KR20200066664A (ko) 세균 감염증을 치료하는 방법
JP2025500088A (ja) Ｆｅｎｍ及びアセチルコリンエステラーゼ阻害剤をベースとする新規相乗的組合せ
JP2025529123A (ja) 急性ストレス障害を処置するための方法及び組成物
US20210052608A1 (en) Methods of treating bacterial infections with minocycline
Bikowski Demystifying anti‐inflammatory dose antibiotics for management of rosacea
JPWO2009025091A1 (ja) 線維筋痛症治療用医薬組成物
UA146303U (uk) Спосіб симптоматичного лікування болю
JP2019531329A (ja) 女性の性機能障害を治療する医薬組成物および方法
HK1155659B (en) Pharmaceutical composition for treatment of fibromyalgia
HK1155659A1 (en) Pharmaceutical composition for treatment of fibromyalgia